EZH2 and non-small cell lung carcinoma: In summary, our study reveal that the co-administration of EZH2 inhibitors with EGFR-TKIs may be feasible for the treatment of EGFR wild-type (WT) NSCLC in patients who refuse traditional chemotherapy.